Literature DB >> 3104518

Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins.

M C Cheung, A C Wolf, K D Lum, J H Tollefson, J J Albers.   

Abstract

Two types of A-I-containing lipoproteins are found in human high density lipoproteins (HDL): particles with A-II (Lp(A-I with A-II] and particles without A-II (Lp(A-I without A-II]. We have studied the distribution of lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer (CET) activities in these particles. Lp(A-I with A-II) and Lp(A-I without A-II) particles were isolated from ten normolipidemic subjects by anti-A-I and anti-A-II immunosorbents. Most plasma LCAT mass (70 +/- 15%), LCAT (69 +/- 16%), and CET (81 +/- 15%) activities were detected in Lp(A-I without A-II). Some LCAT (mass: 16 +/- 7%, activity: 17 +/- 8%) and CET activities (7 +/- 8%) were detected in Lp(A-I with A-II). To determine the size subspecies that contain LCAT and CET activities, isolated Lp(A-I with A-II) and Lp(A-I without A-II) particles of six subjects were further fractionated by gel filtration column chromatography. In Lp(A-I without A-II), most LCAT and CET activities were associated with different size particles, with the majority of the LCAT and CET activities located in particles with hydrated Stokes diameters of 11.6 +/- 0.4 nm and 10.0 +/- 0.6 nm, respectively. In Lp(A-I with A-II), most of the LCAT and CET activities were located in particles similar in size: 11.1 +/- 0.4 nm and 10.6 +/- 0.3 nm, respectively. Ultracentrifugation of A-I-containing lipoproteins resulted in dissociation of both LCAT and CET activities from the particles. Furthermore, essentially all CET and LCAT activities were recovered in the non-B-containing plasma obtained by anti-LDL immunoaffinity chromatography. This report, therefore, provides direct evidence for the association of LCAT and CET protein with A-I-containing lipoproteins. Our conclusions pertain to fasting normolipidemic subjects and may not be applicable to hyperlipidemic or nonfasting subjects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3104518

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  16 in total

1.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins.

Authors:  S T Kunitake; M R Jarvis; R L Hamilton; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

2.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

Review 3.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

4.  Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid.

Authors:  Norman E Miller; Waldemar L Olszewski; Hiroaki Hattori; Irina P Miller; Takeshi Kujiraoka; Tomoichiro Oka; Tadao Iwasaki; M Nazeem Nanjee
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-11       Impact factor: 4.310

5.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 6.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

7.  Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects.

Authors:  Y L Marcel; R McPherson; M Hogue; H Czarnecka; Z Zawadzki; P K Weech; M E Whitlock; A R Tall; R W Milne
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux.

Authors:  M C Cheung; A J Mendez; A C Wolf; R H Knopp
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

9.  Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.

Authors:  D J Rader; K Ikewaki; N Duverger; H Schmidt; H Pritchard; J Frohlich; M Clerc; M F Dumon; T Fairwell; L Zech
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction.

Authors:  F Fumeron; D Betoulle; G Luc; I Behague; S Ricard; O Poirier; R Jemaa; A Evans; D Arveiler; P Marques-Vidal
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.